Until the Phase 2 trial results confirm that the X22 cigarette is an effective "drug" and/or the FDA mandates that the tobacco manuf must reduce the amount of nicotine and/or they (tobacco manuf) can label reduced nicotine cigarettes as "moderate risk" products, there is no need to consider it as immediate revenue.